Enbrel® is approved across 6 indications, including paediatric indications.¹
Moderate to severe RA
Enbrel®, alone or in combination with MTX, has been shown to reduce the rate of progression of joint damage, as measured by an X-ray, and to improve physical function.3
Enbrel® provides long-term RA control
Adapted from Marchesoni A, et al. 2009.
P = 0.027 Enbrel versus, Adalimumab and Infliximab. Not a head to head comparison.
Adapted from Iannone F, et al. 2012.
P<0.0001 for Enbrel® versus other treatment groups. Not a head-to-head comparison.
Numerically, more patients continued on Enbrel® at 6 months to 5 years than on adalimumab or infliximab.8
Number of patients evaluated (number of studies included)
Adapted from Arora A, et al. 2013.
Pooled drug survival rate. Biologic-naïve group. Not a head-to-head comparison. There were differences in baseline characteristics of patients among different registries.9
An RA patient with an increased risk of serious infections
An MTX-IR patient
An RA patient considering starting a family
An elderly-onset RA patient
A young patient worried about the lifelong impact of RA
A young RA patient worried about treatments that lose effectiveness over time
ADA, adalimumab; COPD, chronic obstructive pulmonary disease; DMARD, disease-modifying antirheumatic drug; EMA, European Medicines Agency; ETN, etanercept; GISEA, Gruppo Italiano Studio Early Arthritis; INF, infliximab; LORHEN, Lombardy Rheumatology Network; MTX, methotrexate; MTX-IR, methotrexate-inadequate responder; RA, rheumatoid arthritis; TNFi, tumour necrosis factor inhibitor.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.